# Xenon Begins Q1 2027 Azetukalner Study

> Xenon Pharmaceuticals starts Phase 3b/4 trial for focal seizures in Q1 2027.
- Title: Xenon Begins Q1 2027 Azetukalner Study · TokenPost | Shortify
- Summary: Xenon Pharmaceuticals starts Phase 3b/4 trial for focal seizures in Q1 2027. Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner for focal…
- Keywords: xenon pharmaceuticals, azetukalner, phase 3b/4 study, focal seizures, u.s. approval, drug application, crypto, TokenPost
- Source: TokenPost — https://tokenpost.com/news/business/52797
- Published: 2026-11-10T04:12:38+00:00
- Read time: 1 min
- Topics: xenon pharmaceuticals, azetukalner, phase 3b/4 study, focal seizures, u.s. approval, drug application, crypto, finance
## Xenon Pharmaceuticals
Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner in Q1 2027 as it pursues U.S. approval for focal seizures after filing a new drug application in Q3 2026.
## Financial Position
Xenon ended Q3 with $1.2 billion in cash, cash equivalents and marketable securities. The company expects those resources to fund operations into 2029 under current plans.
## X-NOVA2 Results
Xenon expects topline results from X-NOVA2, a study in major depressive disorder (MDD), in December 2026.
## Key takeaway

Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner for focal seizures in Q1 2027 after filing a new drug application in Q3 2026.